Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. 2011

Takeshi Hanagiri, and Masakazu Sugaya, and Masaru Takenaka, and Sohich Oka, and Tetsuro Baba, and Yoshiki Shigematsu, and Yoshika Nagata, and Hidehiko Shimokawa, and Hidetaka Uramoto, and Mitsuhiro Takenoyama, and Kosei Yasumoto, and Fumihiro Tanaka
Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Yahatanishi, Iseigaoka 1-1, Yahatanishi-ku, Kitakyushu 807, Japan. hanagiri@med.uoeh-u.ac.jp

OBJECTIVE This study investigated the preoperative serum levels of CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. METHODS This study evaluated 341 patients who had undergone a complete resection for stage I NSCLC between 2002 and 2008. RESULTS The patients included 193 males and 148 females. The mean age of the patients was 69.2 years (range: 19-88). The histological types included 264 adenocarcinomas, 56 squamous cell carcinomas, 11 large cell carcinomas, and 10 other types of carcinoma. A pneumonectomy was performed in 2 patients, a bilobectomy in 7, a lobectomy in 255, a segmentectomy in 46, and partial resection of the lung in 31 patients. The positive rates for CYFRA 21-1 in the adenocarcinoma and squamous cell carcinoma patients were 33.3% and 76.8%, respectively. The positive rates for CEA in adenocarcinoma and squamous cell carcinoma patients were 23.8% and 26.8%, respectively. The 5-year survival rate after surgery in the normal CYFRA 21-1 group and the high CYFRA 21-1 groups were 92.8% and 75.4%, respectively, in the patients with stage I NSCLC. There was a significant difference between the 2 groups (p<0.0001). The 5-year survival rate according to the serum level of CEA in the patients with stage I NSCLC were 88.3% for the normal group and 76.3% for the high group. In a multivariate analysis using the variables found to be significant prognostic factors in univariate analysis, a high CYFRA 21-1 level was found to be a significant independent prognostic factor (95% confidence interval 1.213-5.442, p=0.014). CONCLUSIONS A high preoperative CYFRA 21-1 level was a significant independent prognostic factor in patients with stage I NSCLC. The patients with a high CYFRA 21-1 level should carefully followed-up to rule out occult metastasis. Further clinical studies will be necessary to evaluate the efficacy of adjuvant therapy for the patients selected according to this criterion.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011300 Preoperative Care Care given during the period prior to undergoing surgery when psychological and physical preparations are made according to the special needs of the individual patient. This period spans the time between admission to the hospital to the time the surgery begins. (From Dictionary of Health Services Management, 2d ed) Care, Preoperative,Preoperative Procedure,Preoperative Procedures,Procedure, Preoperative,Procedures, Preoperative
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011956 Receptors, Cell Surface Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands. Cell Surface Receptor,Cell Surface Receptors,Hormone Receptors, Cell Surface,Receptors, Endogenous Substances,Cell Surface Hormone Receptors,Endogenous Substances Receptors,Receptor, Cell Surface,Surface Receptor, Cell
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Takeshi Hanagiri, and Masakazu Sugaya, and Masaru Takenaka, and Sohich Oka, and Tetsuro Baba, and Yoshiki Shigematsu, and Yoshika Nagata, and Hidehiko Shimokawa, and Hidetaka Uramoto, and Mitsuhiro Takenoyama, and Kosei Yasumoto, and Fumihiro Tanaka
January 2008, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Takeshi Hanagiri, and Masakazu Sugaya, and Masaru Takenaka, and Sohich Oka, and Tetsuro Baba, and Yoshiki Shigematsu, and Yoshika Nagata, and Hidehiko Shimokawa, and Hidetaka Uramoto, and Mitsuhiro Takenoyama, and Kosei Yasumoto, and Fumihiro Tanaka
October 2007, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery,
Takeshi Hanagiri, and Masakazu Sugaya, and Masaru Takenaka, and Sohich Oka, and Tetsuro Baba, and Yoshiki Shigematsu, and Yoshika Nagata, and Hidehiko Shimokawa, and Hidetaka Uramoto, and Mitsuhiro Takenoyama, and Kosei Yasumoto, and Fumihiro Tanaka
September 2017, Oncotarget,
Takeshi Hanagiri, and Masakazu Sugaya, and Masaru Takenaka, and Sohich Oka, and Tetsuro Baba, and Yoshiki Shigematsu, and Yoshika Nagata, and Hidehiko Shimokawa, and Hidetaka Uramoto, and Mitsuhiro Takenoyama, and Kosei Yasumoto, and Fumihiro Tanaka
July 2010, Anticancer research,
Takeshi Hanagiri, and Masakazu Sugaya, and Masaru Takenaka, and Sohich Oka, and Tetsuro Baba, and Yoshiki Shigematsu, and Yoshika Nagata, and Hidehiko Shimokawa, and Hidetaka Uramoto, and Mitsuhiro Takenoyama, and Kosei Yasumoto, and Fumihiro Tanaka
April 2004, Respiratory medicine,
Takeshi Hanagiri, and Masakazu Sugaya, and Masaru Takenaka, and Sohich Oka, and Tetsuro Baba, and Yoshiki Shigematsu, and Yoshika Nagata, and Hidehiko Shimokawa, and Hidetaka Uramoto, and Mitsuhiro Takenoyama, and Kosei Yasumoto, and Fumihiro Tanaka
June 2019, Translational lung cancer research,
Takeshi Hanagiri, and Masakazu Sugaya, and Masaru Takenaka, and Sohich Oka, and Tetsuro Baba, and Yoshiki Shigematsu, and Yoshika Nagata, and Hidehiko Shimokawa, and Hidetaka Uramoto, and Mitsuhiro Takenoyama, and Kosei Yasumoto, and Fumihiro Tanaka
January 2004, Anticancer research,
Takeshi Hanagiri, and Masakazu Sugaya, and Masaru Takenaka, and Sohich Oka, and Tetsuro Baba, and Yoshiki Shigematsu, and Yoshika Nagata, and Hidehiko Shimokawa, and Hidetaka Uramoto, and Mitsuhiro Takenoyama, and Kosei Yasumoto, and Fumihiro Tanaka
January 1998, Anticancer research,
Takeshi Hanagiri, and Masakazu Sugaya, and Masaru Takenaka, and Sohich Oka, and Tetsuro Baba, and Yoshiki Shigematsu, and Yoshika Nagata, and Hidehiko Shimokawa, and Hidetaka Uramoto, and Mitsuhiro Takenoyama, and Kosei Yasumoto, and Fumihiro Tanaka
January 1999, Anticancer research,
Takeshi Hanagiri, and Masakazu Sugaya, and Masaru Takenaka, and Sohich Oka, and Tetsuro Baba, and Yoshiki Shigematsu, and Yoshika Nagata, and Hidehiko Shimokawa, and Hidetaka Uramoto, and Mitsuhiro Takenoyama, and Kosei Yasumoto, and Fumihiro Tanaka
July 2011, Experimental and therapeutic medicine,
Copied contents to your clipboard!